Arrowhead Pharmaceuticals (ARWR) Cash & Current Investments (2010 - 2026)

Arrowhead Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• Quarterly Cash & Current Investments rose 62.57% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 62.57% YoY) and the FY2025 annual result came in at $919.4 million, up 35.01% from the prior year.
• Cash & Current Investments was $1.8 billion for Q1 2026 at Arrowhead Pharmaceuticals, up from $916.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $1.8 billion in Q1 2026 and bottomed at $108.0 million in Q3 2022.
• A 5-year average of $623.7 million and a median of $501.8 million in 2022 frame the typical range for Cash & Current Investments.
• Peak annual rise in Cash & Current Investments reached 345.93% in 2022, while the deepest fall reached 65.29% in 2022.
• Arrowhead Pharmaceuticals' Cash & Current Investments stood at $501.8 million in 2022, then sank by 56.1% to $220.3 million in 2023, then jumped by 150.95% to $552.9 million in 2024, then soared by 65.79% to $916.6 million in 2025, then soared by 94.64% to $1.8 billion in 2026.
• Business Quant data shows ARWR's Cash & Current Investments at $1.8 billion in Q1 2026, $916.6 million in Q4 2025, and $919.4 million in Q3 2025.